UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 17, 2016
OSIRIS THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
|
Maryland |
|
001-32966 |
|
71-0881115 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
7015 Albert Einstein Drive, Columbia, Maryland |
|
21046 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (443) 545-1800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
(a) On March 17, 2016, Osiris Therapeutics, Inc. (the “Company”) received a deficiency letter from The NASDAQ Stock Market (“NASDAQ”) indicating that, as a result of the Company not timely filing its Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”), the Company failed to comply with the periodic filing requirements for continued listing set forth in Rule 5250(c)(1) of the NASDAQ Listing Rules. NASDAQ has provided the Company until May 16, 2016 to submit a plan to regain compliance. The Company intends to separately issue a press release notifying their public of the deficiency letter promptly after the filing of this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
OSIRIS THERAPEUTICS, INC. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ GREGORY I. LAW |
|
|
|
|
Gregory I. Law |
|
|
|
|
Chief Financial Officer |
Date: March 22, 2016